AccuMetab™ Human CYP1B1∗ 3 Enzyme, Catalytically Active

CAT#: ITS-0426-YL25
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Human CYP1B1∗ 3 variant for precise pharmacogenetic Phase I profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
The CYP1B1∗ 3 polymorphism alters the enzyme's catalytic properties, often shifting its efficiency in metabolizing endogenous estrogens and exogenous toxins. This variant is a key investigative tool in predictive toxicology for understanding individualized susceptibility to environmental carcinogens and cancer risks.
Key Features
Polymorphic extrahepatic variant model; Shifts specific estrogenic clearance pathways; Essential for environmental carcinogen susceptibility panels; Supplied in controlled, low-reductase formats
Applications
Drug Metabolism Studies, Phenotype Comparison, Polymorphism Impact
Research Areas
ADME; Oncology; Pharmacogenetics
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry